Loading data for NNVC — first visit, this takes a few seconds.

アラート

NanoViricides Inc. (NNVC)

NYSE American: NNVC · リアルタイム株価 · USD

1.35

-0.01 (-0.74%)

終値時点： Aug 19, 2026, 2:03 PM

-0.74% (1D)

データがありません

買気配	n/a
時価総額	35.19M
売上高（TTM）	n/a
純利益（TTM）	-8.09M
ベータ	1.69
EPS（TTM）	-0.44
PER（TTM）	n/a
予想PER	-3.94
PBR（TTM）	3.26
PSR（TTM）	n/a
Earnings Date	n/a

売気配	1.39
出来高	256,381
平均出来高（20日）	907,890
始値	1.35
前日終値	1.36
当日レンジ	1.32 - 1.38
52週レンジ	0.85 - 2.23
アナリスト	Strong Buy
目標株価	6 (344.44%)
配当	n/a
権利落ち日	n/a

NNVCについて

NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs to combat viral infections. The company's product portfolio includes NV-387 drug candidate developed for RSV and influenza indications and has completed phase 1a/1b human clinical trial for the evaluation of safety and tolerability; NV-387 as an active ingredient of drug product formulations for the treatment of COVID infections com...

[続きを読む]

業種 Biotechnology

セクター Healthcare

IPO日 Oct 26, 2005

従業員数 7

上場取引所 NYSE American

ティッカー NNVC

ウェブサイト https://www.nanoviricides.com

企業情報の全文

業績

2025年のNanoViricidesの売上高は0で、前年の0からundefined%の増加でした。利益は-9.47Mで、14.14%の増加でした。

財務諸表

アナリスト予想

2件のアナリスト評価によると、NNVC株の平均レーティングは「Strong Buy」です。12か月後の目標株価は6で、直近株価から344.44%の上昇余地となります。

株価予想

決算サプライズ

NanoViricidesはMay 15, 2026に四半期決算を発表しました：

売上高は $0 で、予想を下回りました $0, うち NaN% の前年比増加にあたります.

EPSは -0.09 で、予想を下回りました -0.01, うち 43.75% の前年比増加にあたります.

ニュース

1か月前 · Stocktwits

NNVC Stock In The Limelight After This Analyst Sees A 350% Upside Potential – Everything To Know About Its Experimental Drug For Ebola

The biotech firm said it is progressing towards a Phase II clinical trial of its antiviral drug NV-387 for the Bundibugyo Ebola outbreak in the Democratic Republic of Congo.

1か月前 · IPO-Edge.com

REPLAY: Fireside Chat with NanoViricides President & Exec. Chairman Anil R. Diwan

Watch Fireside Chat Below, or Click HERE: Exec Edge hosted a fireside chat with NanoViricides, Inc. (NYSE: NNVC) President and Executive Chairman Anil R. Diwan, PhD, moderated by IPO Edge […]

3か月前 · Proactive

NanoViricides closes $2M direct offering

NanoViricides (NYSE-A:NNVC) announced the closing of its previously disclosed registered direct offering, raising about $2 million in gross proceeds before fees and expenses. The clinical-stage antivi...

3か月前 · Proactive

NanoViricides says its broad-spectrum antiviral could help tackle Ebola strain behind Congo outbreak

NanoViricides (NYSE-A:NNVC), the US clinical-stage drugmaker, has said its lead drug candidate NV-387 could be effective against the Bundibugyo strain of Ebola virus that has prompted the World Health...

3か月前 · Proactive

NanoViricides to raise $2M in registered direct offering

NanoViricides (NYSE-A:NNVC) said it has entered into a securities purchase agreement with a single institutional investor for gross proceeds of approximately $2 million in a registered direct offering...

2ページ中1ページ

NanoViricides Inc. (NNVC)